These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23056335)

  • 21. Reproductive factors, tumor estrogen receptor status and contralateral breast cancer risk: results from the WECARE study.
    Sisti JS; Bernstein JL; Lynch CF; Reiner AS; Mellemkjaer L; Brooks JD; Knight JA; Bernstein L; Malone KE; Woods M; Liang X; John EM;
    Springerplus; 2015; 4():825. PubMed ID: 26751177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis.
    Akdeniz D; Schmidt MK; Seynaeve CM; McCool D; Giardiello D; van den Broek AJ; Hauptmann M; Steyerberg EW; Hooning MJ
    Breast; 2019 Apr; 44():1-14. PubMed ID: 30580169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women.
    Yoon TI; Kwak BS; Yi OV; Kim S; Um E; Yun KW; Shin HN; Lee S; Sohn G; Chung IY; Kim J; Ko BS; Lee JW; Son BH; Ahn SH; Kim HJ
    Breast Cancer Res Treat; 2019 Feb; 173(3):657-665. PubMed ID: 30377870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer.
    Hegde JV; Wang X; Attai DJ; DiNome ML; Kusske A; Hoyt AC; Hurvitz SA; Weidhaas JB; Steinberg ML; McCloskey SA
    Breast Cancer Res Treat; 2017 Nov; 166(1):145-156. PubMed ID: 28702891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of estrogen receptor-specific breast cancer by family history of estrogen receptor subtypes and other cancers.
    Wang QL; Zhang Y; Zeng E; Grassmann F; He W; Czene K
    J Natl Cancer Inst; 2023 Sep; 115(9):1020-1028. PubMed ID: 37243749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer.
    Li CI; Daling JR; Porter PL; Tang MT; Malone KE
    Cancer Res; 2009 Sep; 69(17):6865-70. PubMed ID: 19706753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study.
    Langballe R; Mellemkjær L; Malone KE; Lynch CF; John EM; Knight JA; Bernstein L; Brooks J; Andersson M; Reiner AS; Liang X; Woods M; Concannon PJ; ; Bernstein JL
    Breast Cancer Res; 2016 Jul; 18(1):65. PubMed ID: 27400983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
    Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
    Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen-receptor status and risk of contralateral breast cancer following DCIS.
    Stout NK; Cronin AM; Uno H; Ozanne EM; Hassett MJ; Frank ES; Greenberg CC; Punglia RS
    Breast Cancer Res Treat; 2018 Oct; 171(3):777-781. PubMed ID: 29946862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour?
    Coradini D; Oriana S; Mariani L; Miceli R; Bresciani G; Marubini E; Di Fronzo G
    Eur J Cancer; 1998 May; 34(6):825-30. PubMed ID: 9797693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
    Swain SM; Wilson JW; Mamounas EP; Bryant J; Wickerham DL; Fisher B; Paik S; Wolmark N
    J Natl Cancer Inst; 2004 Apr; 96(7):516-23. PubMed ID: 15069113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis.
    Liu J; Jiang W; Mao K; An Y; Su F; Kim BY; Liu Q; Jacobs LK
    Breast Cancer Res Treat; 2015 Apr; 150(2):439-45. PubMed ID: 25764167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer.
    Li CI; Malone KE; Weiss NS; Daling JR
    J Natl Cancer Inst; 2001 Jul; 93(13):1008-13. PubMed ID: 11438566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between diabetes and risk of second primary contralateral breast cancer.
    Li CI; Daling JR; Tang MT; Malone KE
    Breast Cancer Res Treat; 2011 Jan; 125(2):545-51. PubMed ID: 20625814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of radiotherapy for the first tumor on aggressiveness of contralateral breast cancer.
    Sandberg ME; Alkner S; Hartman M; Eloranta S; Rydén L; Ploner A; Adami HO; Hall P; Czene K
    Int J Cancer; 2013 May; 132(10):2388-94. PubMed ID: 23034813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry.
    Prater J; Valeri F; Korol D; Rohrmann S; Dehler S
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):365-71. PubMed ID: 26298838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer.
    Bessonova L; Taylor TH; Mehta RS; Zell JA; Anton-Culver H
    Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):389-96. PubMed ID: 21217087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based study.
    Vichapat V; Garmo H; Holmqvist M; Liljegren G; Wärnberg F; Lambe M; Fornander T; Adolfsson J; Lüchtenborg M; Holmberg L
    J Clin Oncol; 2012 Oct; 30(28):3478-85. PubMed ID: 22927521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Declining second primary ovarian cancer after first primary breast cancer.
    Schonfeld SJ; Berrington de Gonzalez A; Visvanathan K; Pfeiffer RM; Anderson WF
    J Clin Oncol; 2013 Feb; 31(6):738-43. PubMed ID: 23284037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
    Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.